Page last updated: 2024-12-06

disobutamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Disobutamide is a class Ia antiarrhythmic drug that acts by blocking sodium channels and prolonging the action potential duration. It is synthesized via a multi-step process that involves the reaction of a substituted benzoyl chloride with an amine, followed by a cyclization reaction. Disobutamide was initially developed for the treatment of atrial fibrillation and other supraventricular tachycardias. However, its use was limited due to its potential side effects, including hypotension, dizziness, and bradycardia. Despite its limited clinical application, disobutamide has been the subject of ongoing research due to its unique pharmacological properties. Studies have investigated its potential for treating cardiac arrhythmias in specific patient populations and its potential role in the management of other conditions, such as heart failure.'

Cross-References

ID SourceID
PubMed CID68566
CHEMBL ID276177
CHEBI ID188656
SCHEMBL ID123603
MeSH IDM0095639

Synonyms (28)

Synonym
sc-31828 ,
disobutamide
D03871
disobutamide (usan/inn)
68284-69-5
CHEMBL276177
CHEBI:188656
2-(2-chlorophenyl)-2-[2-[di(propan-2-yl)amino]ethyl]-4-piperidin-1-ylbutanamide
disobutamidum
disobutamidum [inn-latin]
disobutamida [inn-spanish]
alpha-(o-chlorophenyl)-alpha-(2-(diisopropylamino)ethyl)-1-piperidinebutyramide
sc 31828
4izg3m7xvp ,
1-piperidinebutanamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-(2-chlorophenyl)-
disobutamida
disobutamide [usan:inn]
unii-4izg3m7xvp
disobutamide [usan]
1-piperidinebutanamide, .alpha.-(2-(bis(1-methylethyl)amino)ethyl)-.alpha.-(2-chlorophenyl)-
alpha-(o-chlorophenyl)-alpha-[2-(diisopropylamino)ethyl]-1-piperidinebutyramide
disobutamide [inn]
SCHEMBL123603
2-(2-chlorophenyl)-4-(diisopropylamino)-2-[2-(1-piperidinyl)ethyl]butanamide
Q27259679
alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-(2-chlorophenyl)-1-piperidinebutanamide
DTXSID80867557
AKOS040746777

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID56512Activity duration index was evaluated in mixed-breed or Beagle dogs after intravenous administration.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID60406Compound was evaluated for onset of action after oral administration at a dose 25 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID57000Antiarrhythmic activity was evaluated in mixed-breed or Beagle dogs after intravenous administration.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID59401Minimum effective dose evaluated in mixed-breed or Beagle dogs after intravenous administration1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID60404Compound was evaluated for onset of action after oral administration at a dose 12 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID540243Phospholipidosis-positive literature compound observed in monkey
AID235407Therapeutic ratio in mixed-breed or Beagle dogs after intravenous administration of the compound.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID63473Compound was evaluated for maximum reduction of ectopic beats after oral administration at a dose 15 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID58769Compound was evaluated for duration of action after oral administration at a dose 25 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID540237Phospholipidosis-positive literature compound observed in rat
AID540239Phospholipidosis-positive literature compound observed in dog
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID58767Compound was evaluated for duration of action after oral administration at a dose 12 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID60405Compound was evaluated for onset of action after oral administration at a dose 15 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID58768Compound was evaluated for duration of action after oral administration at a dose 15 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID58746Compound was evaluated for maximum reduction of ectopic beats after oral administration at a dose 12 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
AID63474Compound was evaluated for maximum reduction of ectopic beats after oral administration at a dose 25 mg/kg to dog.1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Synthesis and antiarrhythmic activity of alpha, alpha-bis[(dialkylamino)alkyl]phenylacetamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (76.92)18.7374
1990's1 (7.69)18.2507
2000's1 (7.69)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.67 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]